232 related articles for article (PubMed ID: 17363484)
1. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.
Skobeleva N; Menon S; Weber L; Golemis EA; Khazak V
Mol Cancer Ther; 2007 Mar; 6(3):898-906. PubMed ID: 17363484
[TBL] [Abstract][Full Text] [Related]
2. A two-hybrid approach to identify inhibitors of the RAS-RAF interaction.
Khazak V; Eyrisch S; Kato J; Tamanoi F; Golemis EA
Enzymes; 2013; 33 Pt A():213-48. PubMed ID: 25033807
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.
Kato-Stankiewicz J; Hakimi I; Zhi G; Zhang J; Serebriiskii I; Guo L; Edamatsu H; Koide H; Menon S; Eckl R; Sakamuri S; Lu Y; Chen QZ; Agarwal S; Baumbach WR; Golemis EA; Tamanoi F; Khazak V
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14398-403. PubMed ID: 12391290
[TBL] [Abstract][Full Text] [Related]
4. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
5. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Langdon CG; Wiedemann N; Held MA; Mamillapalli R; Iyidogan P; Theodosakis N; Platt JT; Levy F; Vuagniaux G; Wang S; Bosenberg MW; Stern DF
Oncotarget; 2015 Nov; 6(35):37410-25. PubMed ID: 26485762
[TBL] [Abstract][Full Text] [Related]
6. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
[TBL] [Abstract][Full Text] [Related]
7. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
[TBL] [Abstract][Full Text] [Related]
10. Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin.
Hung LVM; Moon JY; Ryu JY; Cho SK
Phytomedicine; 2019 Oct; 63():153000. PubMed ID: 31280139
[TBL] [Abstract][Full Text] [Related]
11. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
[TBL] [Abstract][Full Text] [Related]
13. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
14. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
Honore S; Kamath K; Braguer D; Horwitz SB; Wilson L; Briand C; Jordan MA
Cancer Res; 2004 Jul; 64(14):4957-64. PubMed ID: 15256469
[TBL] [Abstract][Full Text] [Related]
15. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
17. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
Hu Y; Bally M; Dragowska WH; Mayer L
Mol Cancer Ther; 2003 Jul; 2(7):641-9. PubMed ID: 12883037
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
20. Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
Rosetti M; Zoli W; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Granato AM; Amadori D; Silvestrini R
J Cell Physiol; 2007 Sep; 212(3):710-6. PubMed ID: 17458894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
